GlobalData on MSN1d
Boehringer seeks approval of lung disease drug after second Phase III success
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Illustrative photo Boehringer Ingelheim Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast ...
pulmonologyadvisor1d
ILD Short-Term Survival May Be Improved With Pulmonary Rehabilitation
The median length of survival for individuals with ILD who completed pulmonary rehabilitation was 6.1 years vs 4.7 years in the control group. Pulmonary rehabilitation (PR) may improve survival at 5 ...
Managed Healthcare Executive5d
ATS Guidelines Highlight Benefits of Pulmonary Rehabilitation
Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved ...
pharmaphorum1d
Boehringer drug scores in another pulmonary fibrosis trial
The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...
PMLiVE9h
Boehringer’s nerandomilast shows promise in phase 3 pulmonary fibrosis study
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
FierceBiotech2d
Boehringer widens fibrosis drug's approval path after boosting lung function in 2nd phase 3 trial
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Pharmabiz15h
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...
Too Old to Operate5d
Survey of Genetic Testing and ILD Screening Practices
The following is a summary of “Diagnosis, screening, and follow-up of patients with familial interstitial lung disease: ...
York Hospital welcomes Dr. Marta Kokoszynska as new medical director
"We are thrilled to welcome Dr. Kokoszynska to our team," said Patrick A. Taylor, York Hospital president and CEO. "Her ...
Boehringer Ingelheim Limited: Boehringer's nerandomilast meets primary endpoint in Phase III study FIBRONEER-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...